CollPlant Biotechnologies (CLGN) Research & Development (2017 - 2025)

CollPlant Biotechnologies has reported Research & Development for 9 years, with the latest figure at $2.0 million in Q4 2025.

• For the quarter ending Q4 2025, Research & Development fell 22.14% year-over-year to $2.0 million; the trailing twelve-month figure through Dec 2025 stood at $8.2 million (down 22.14% YoY), and the FY2025 full-year result was $8.2 million, down 22.14% from the prior year.
• Research & Development for Q4 2025 stood at $2.0 million, down from $2.1 million in the prior quarter.
• The five-year high for Research & Development was $3.1 million in Q4 2023, with the low at $1.6 million in Q1 2021.
• Historically, Research & Development has averaged $2.4 million across 5 years, with a median of $2.3 million in 2022.
• The largest YoY upside for Research & Development was 101.6% in 2021 against a maximum downside of 99.79% in 2021.
• CollPlant Biotechnologies' Research & Development stood at $2.2 million in 2021, then grew by 20.47% to $2.6 million in 2022, then rose by 18.05% to $3.1 million in 2023, then retreated by 18.31% to $2.5 million in 2024, then fell by 22.14% to $2.0 million in 2025.
• The last three Research & Development figures came in at $2.0 million (Q4 2025), $2.1 million (Q3 2025), and $2.0 million (Q2 2025), per Business Quant data.